SGLT2i treatment significantly reduces albumin excretion in patients with T2D and microalbuminuria (urinary albumin-to-creatinine ratio [UACR] of 30–300 mg/g) or macroalbuminuria (UACR >300 mg/g), including patients receiving drugs that block the RAAS [71,72,73]. The gene discussed is ALB; the disease is type 2 diabetes mellitus.